Literature DB >> 9234804

Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats.

F De Bernardis1, M Boccanera, D Adriani, E Spreghini, G Santoni, A Cassone.   

Abstract

The role of antibodies (Abs) in the resistance to vaginal infection by Candida albicans was investigated by using a rat vaginitis model. Animals receiving antimannoprotein (anti-MP) and anti-aspartyl proteinase (Sap) Ab-containing vaginal fluids from rats clearing a primary C. albicans infection showed a highly significant level of protection against vaginitis compared to animals given Ab-free vaginal fluid from noninfected rats. Preabsorption of the Ab-containing fluids with either one or both proteins MP and Sap sequentially reduced or abolished, respectively, the level of protection. A degree of protection against vaginitis was also conferred by postinfectious administration of anti-Sap and anti-MP monoclonal antibodies (provided the latter were directed against mannan rather than protein epitopes of MP) and by intravaginal immunization with a highly purified, polysaccharide-free Sap preparation. Postinfectious administration of pepstatin A, a potent Sap inhibitor, greatly accelerated the clearance of C. albicans from rat vagina. No anti-MP or anti-Sap Abs were elicited during a C. albicans vaginal infection of congenitally athymic nude rats. Although they were as able as their euthymic counterparts to clear the primary infection, these animals did not show increased resistance to a rechallenge, demonstrating that induction of anticandidal protection in normal rats was a thymus-dependent Ab response. Overall, our data strengthen the concept that Abs against some defined Candida antigens are relevant in the mechanism of acquired anticandidal protection in vaginitis. The T-cell dependence of this protection may also provide a link between cell-mediated and humoral immunity in vaginal infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234804      PMCID: PMC175481          DOI: 10.1128/iai.65.8.3399-3405.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Mucosal and systemic candidiasis in congenitally immunodeficient mice.

Authors:  M T Cantorna; E Balish
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

2.  A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.

Authors:  A Mencacci; A Torosantucci; R Spaccapelo; L Romani; F Bistoni; A Cassone
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

3.  Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.

Authors:  P L Fidel; M E Lynch; J D Sobel
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

4.  Evidence for adhesin activity in the acid-stable moiety of the phosphomannoprotein cell wall complex of Candida albicans.

Authors:  T Kanbe; J E Cutler
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis.

Authors:  F De Bernardis; A Cassone; J Sturtevant; R Calderone
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

6.  Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.

Authors:  P L Fidel; M E Lynch; D H Conaway; L Tait; J D Sobel
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

7.  Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans.

Authors:  B Hube; M Monod; D A Schofield; A J Brown; N A Gow
Journal:  Mol Microbiol       Date:  1994-10       Impact factor: 3.501

8.  Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies.

Authors:  L Polonelli; F De Bernardis; S Conti; M Boccanera; M Gerloni; G Morace; W Magliani; C Chezzi; A Cassone
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

9.  Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection.

Authors:  A Cassone; M Boccanera; D Adriani; G Santoni; F De Bernardis
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis.

Authors:  P L Fidel; M E Lynch; J D Sobel
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more
  62 in total

1.  Beta-1,2-mannosylation of Candida albicans mannoproteins and glycolipids differs with growth temperature and serotype.

Authors:  P A Trinel; T Jouault; J E Cutler; D Poulain
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

2.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

3.  A fungicidal monoclonal antibody protects against murine invasive candidiasis.

Authors:  María J Sevilla; Beatriz Robledo; Aitor Rementeria; María D Moragues; José Pontón
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis.

Authors:  Flavia De Bernardis; Roberta Lucciarini; Maria Boccanera; Consuelo Amantini; Silvia Arancia; Stefania Morrone; Michela Mosca; Antonio Cassone; Giorgio Santoni
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 5.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

Review 6.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

Review 7.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus.

Authors:  R Buissa-Filho; R Puccia; A F Marques; F A Pinto; J E Muñoz; J D Nosanchuk; L R Travassos; C P Taborda
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

9.  Candida-specific antibodies during experimental vaginal candidiasis in mice.

Authors:  Karen L Wozniak; Floyd L Wormley; Paul L Fidel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.